Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer

This is a phase Ib followed by phase II clinical trial evaluating the safety and efficacy of combination of ADG106 with pembrolizumab in patients with metastatic cancers. The Phase Ib dose finding part will include all solid tumor subtypes with treatment refractory disease, while phase II will focus on only patients with TNBC.

Trial Details

NCT ID
NCT05491083
Phase
PHASE1 / PHASE2
Sponsor
National University Hospital, Singapore
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • Pembrolizumab & ADG106 (Phase Ib)
  • Pembrolizumab & ADG106 (Phase II)
Locations (sample)
  • Singapore, Singapore|1.28967,103.85007

Key Eligibility Criteria

  • 21 years and above of age
  • Estimated life expectancy of at least 12 weeks.
  • Has recovered from acute toxicities from prior anti-cancer therapies.
  • Has a tumor lesion that can be safely biopsied and who is willing to undergo tumor biopsy at baseline before starting study treatment

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →